

## **NEWS RELEASE**

### **FOR IMMEDIATE RELEASE**

#### **PROTEA TO PRESENT AT 9<sup>th</sup> ANNUAL LAZARD HEALTHCARE CONFERENCE**

**Morgantown, WV Nov. 8, 2012, 8:30am EST** – Protea Biosciences Group, Inc. (“Protea”), a leading bioanalytics innovator, announced today that Stephen Turner, the company’s CEO, will present at the 9<sup>th</sup> Annual Lazard Healthcare Conference on Wednesday November 14<sup>th</sup>, at the Pierre Hotel in New York City. Protea will join a select group of private healthcare companies that have been invited to present at the Lazard Healthcare Conference.

“We are pleased to have this opportunity to present Protea, and our groundbreaking LAESI technology platform, to the institutional investment community at this year’s Lazard Healthcare Conference,” stated Stephen Turner, Protea’s CEO. “Protea is building a new life science franchise by developing and marketing technology that allows biologists to obtain full biomolecular imaging data on their tissue, cell or biofluid samples in their native state, without sample preparation. For the first time, researchers can obtain mass spectrometric data on live cells and bacterial cell colonies, with results available in the same day.”

Protea’s proprietary LAESI (Laser Ablation Electrospray Ionization) technology allows two and three dimensional distribution profiles of molecules in biological samples for unambiguous drug/target interaction studies, as well as the study of bio-dynamics directly from living cells. Using LAESI mass spectrometry, large numbers of biomolecules can be rapidly identified and spatially mapped to cell structures, tissues, and fluids.

**More information about the upcoming conference can be found at:**

**[http://www.lazardcap.com/conferenceDocs/7041\\_2012%20Lazard%20Capital%20Markets%20Healthcare%20Conference%20Invitation.pdf](http://www.lazardcap.com/conferenceDocs/7041_2012%20Lazard%20Capital%20Markets%20Healthcare%20Conference%20Invitation.pdf)**

#### **About Protea Biosciences Group, Inc.**

Protea is a leader in the field of bioanalytics – the identification and characterization of proteins, metabolites, and other biomolecules, which are the products of all living cells and life forms – technology that is foundational for all pharmaceutical and life science research.

Forward-Looking Statements



**Protea Biosciences, Inc.**

955 Hartman Run Road  
Morgantown, WV 26507  
P: 304.292.2226  
F: 304.292.7101  
[www.proteabio.com](http://www.proteabio.com)

*This press release may contain certain statements relating to future results, which are forward looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, are contained in the Company's filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.*

**For more Information:**

Protea Biosciences, Inc.,  
955 Hartman Run Road, Morgantown, WV 26507  
Phone: 304.292.2226  
Fax: 304.292.7101  
[stephen.turner@proteabio.com](mailto:stephen.turner@proteabio.com)

[www.proteabio.com](http://www.proteabio.com)

<https://proteabio.com/imaging>